ALS News Today Home | ALS News Today
6 天之前 · Diabetes, high cholesterol linked with lower risk of developing ALS. People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) or other motor neuron diseases (MNDs), but heart and metabolism problems are linked with faster disease progression and worse survival rates among people who already have MND.
News Archives - ALS News Today
Top 10 ALS news stories of 2024. Throughout 2024, ALS News Today brought our readers daily coverage of the latest in scientific breakthroughs, treatment advances, and clinical trial updates related to amyotrophic lateral sclerosis (ALS).
Number of ALS cases in US expected to climb 10% by 2030: Study
1 天前 · The number of people living with amyotrophic lateral sclerosis (ALS) in the U.S. is expected to steadily climb — by more than 10% — over this decade, increasing from an estimated 32,800 cases in 2022 to about 36,300 in 2030, according to a new study from researchers with the Centers for Disease Control and Prevention (CDC).
Top 10 ALS news stories of 2024
2024年12月30日 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found to slow ALS disease progression and lower levels of disease-related biomarkers in a small Phase 1 clinical trial. COYA 302 is a combination of an immune signaling molecule called interleukin-2 and a fusion protein called CTLA4-Ig ...
ALS News Today
Recent Posts. Why I named my column ‘Living Well with ALS’ Top 10 ALS news stories of 2024; Choosing how to communicate about ALS — and when
ALS Disease Progression Slowed With Low-dose Aldesleukin: Trial
2022年12月16日 · A pivotal Phase 2 clinical trial called IMODALS (NCT02059759) investigated the effects of low-dose aldesleukin injections in 36 people with ALS. Results showed that three months of treatment significantly increased the number and activity of Tregs compared with a placebo.. Effects of low-dose aldesleukin in MIROCALS
Top 10 ALS stories of 2023 - ALS News Today
2024年1月2日 · No. 9 – Further questions set back European approval of AMX0035. Amylyx Pharmaceuticals’ application seeking the approval of AMX0035 in treating ALS patients across Europe faced a second round of questions from the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. The committee still had major objections to AMX0035 that needed to be addressed ...
Clene granted in-person FDA meeting on CNM-Au8 for ALS
2024年9月24日 · Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held before the end of November, according to the company — to discuss a potential accelerated approval of CNM-Au8 …
Largest ALS patient-based stem cell, biodata resource now open
2024年11月21日 · The largest of its kind, the repository contains biological and clinical data from nearly 1,000 ALS patients, as well as specialized nerve cells called induced pluripotent stem cells (iPSCs) derived from the patients that scientists can use as a resource for advancing ALS research and treatment.. Researchers can access the resources via the online, open-source Answer ALS Neuromine Data Portal ...
Healthcare costs increase as ALS progresses, per Biogen US study
2024年12月23日 · Due to substantial increases in the use of healthcare resources, medical costs in the U.S. for people with amyotrophic lateral sclerosis (ALS) rise significantly as the disease progresses, going from about $31,000 per year in the early disease stage to $122,000 per year in the late stage, a study by Biogen researchers found.